These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 18783957

  • 1. Concentrations of piperacillin-tazobactam in human jaw and hip bone.
    Al-Nawas B, Kinzig-Schippers M, Soergel F, Shah PM.
    J Craniomaxillofac Surg; 2008 Dec; 36(8):468-72. PubMed ID: 18783957
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
    Varghese JM, Jarrett P, Boots RJ, Kirkpatrick CM, Lipman J, Roberts JA.
    Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
    [Abstract] [Full Text] [Related]

  • 3. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
    Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O.
    J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
    [Abstract] [Full Text] [Related]

  • 4. Piperacillin-tazobactam penetration into human pancreatic juice.
    Bertazzoni Minelli E, Benini A, Franco L, Bassi C, Pederzoli P.
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4149-52. PubMed ID: 18809943
    [Abstract] [Full Text] [Related]

  • 5. Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues.
    Incavo SJ, Ronchetti PJ, Choi JH, Wu H, Kinzig M, Sörgel F.
    Antimicrob Agents Chemother; 1994 Apr; 38(4):905-7. PubMed ID: 8031071
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic characteristics of piperacillin/tazobactam.
    Sörgel F, Kinzig M.
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S14-20. PubMed ID: 7962984
    [Abstract] [Full Text] [Related]

  • 7. Penetration of piperacillin/tazobactam (4 g/500 mg) into synovial tissue.
    Boselli E, Breilh D, Debon R, Duflo F, Bel JC, Saux MC, Chassard D, Allaouchiche B.
    J Chemother; 2002 Feb; 14(1):54-8. PubMed ID: 11892900
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
    Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD.
    Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
    [Abstract] [Full Text] [Related]

  • 9. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.
    Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, Kays MB.
    Int J Antimicrob Agents; 2013 Jan; 41(1):52-6. PubMed ID: 23228881
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JÁ, Isla A.
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [Abstract] [Full Text] [Related]

  • 13. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
    Boselli E, Breilh D, Rimmelé T, Guillaume C, Xuereb F, Saux MC, Bouvet L, Chassard D, Allaouchiche B.
    Crit Care Med; 2008 May; 36(5):1500-6. PubMed ID: 18434883
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP.
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [Abstract] [Full Text] [Related]

  • 15. Pulmonary penetration of piperacillin and tazobactam in critically ill patients.
    Felton TW, McCalman K, Malagon I, Isalska B, Whalley S, Goodwin J, Bentley AM, Hope WW.
    Clin Pharmacol Ther; 2014 Oct; 96(4):438-48. PubMed ID: 24926779
    [Abstract] [Full Text] [Related]

  • 16. An improved high-performance liquid chromatographic method with a solid-phase extraction for the determination of piperacillin and tazobactam: application to pharmacokinetic study of different dosage in Chinese healthy volunteers.
    Xia CH, Xiong YQ, Wang GJ.
    Biomed Chromatogr; 2007 Jul; 21(7):680-6. PubMed ID: 17385803
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW, Allen N, Rafferty KD, Fish DN, Toschlog E, Newell M, Waibel B.
    Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock.
    Tamme K, Oselin K, Kipper K, Tasa T, Metsvaht T, Karjagin J, Herodes K, Kern H, Starkopf J.
    Acta Anaesthesiol Scand; 2016 Feb; 60(2):230-40. PubMed ID: 26830215
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
    Sörgel F, Kinzig M.
    Eur J Surg Suppl; 1994 Feb; (573):39-44. PubMed ID: 7524794
    [Abstract] [Full Text] [Related]

  • 20. Dose optimization of piperacillin/tazobactam in critically ill children.
    De Cock PAJG, van Dijkman SC, de Jaeger A, Willems J, Carlier M, Verstraete AG, Delanghe JR, Robays H, Vande Walle J, Della Pasqua OE, De Paepe P.
    J Antimicrob Chemother; 2017 Jul 01; 72(7):2002-2011. PubMed ID: 28387840
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.